Skip to content
Catalyst

methylene blueFinding

Methylene blue has no detected effect on all-cause mortality

no difference foundVery limited evidenceFinding

01 · The sentence it was drawn from

“The study’s primary endpoint, In-hospital mortality, was insignificant between the two groups (38% in the MB group vs. 43% in the control group).”
Quoted verbatim from The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock.
This finding among the 156 findings on its endpoint

methylene blue

All-cause mortality

no difference found

Who
Adults with norepinephrine-refractory vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass; 84 given methylene blue within 24 h postoperatively versus 116 not given it, all on norepinephrine; retrospective single-centre cohort; in-hospital horizon
Dose studied
2 mg/kg intravenous bolus followed by 0.5 mg/kg/h infusion for 12 h

Very limited evidencePMID 39903510 · 2025

02 · The study

Study
cohort
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

Annals of medicine
What else it reported2 findings · 1 compound · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZBH64ZRK69YBH8AVBY6QZY